Vaxart, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven Lo
- Full Time Employees
- 65
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 310 Utah Avenue South San Francisco CA United States of America 94080
- IPO Date
- Dec 11, 1981
- CIK
- 0000072444
- Website
- vaxart.com
- Similar Companies
- Business
- Vaxart, Inc. Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company that discovers, develops and commercializes oral recombinant pill vaccines utilizing its proprietary vector-adjuvant-antigen standardized technology (VAAST) platform, which enables temperature-stable, needle-free administration generating both mucosal and systemic immune responses; its lead development programs encompass a bivalent norovirus vaccine candidate in Phase 2 for GI.1 and GII.4 strains targeting acute gastroenteritis, an oral COVID-19 vaccine (VXA-CoV2-3.3) in Phase 2b trial under BARDA Project NextGen funding up to $460 million comparing efficacy to mRNA boosters, a seasonal influenza vaccine demonstrated comparable efficacy to Fluzone in Phase 2 human challenge studies for H1 strains, and a therapeutic human papillomavirus (HPV) vaccine in preclinical stage targeting HPV-16 and HPV-18 for cervical precancers and lesions. Vaxart, Inc. operates primarily in the United States with global ambitions for its vaccines addressing infectious diseases and oncology indications, serving prophylactic and therapeutic markets for vulnerable populations including infants, adults, seniors and immunocompromised individuals; founded in 2004 and headquartered in South San Francisco, California, the company maintains a license agreement with Altesa Biosciences for Vapendavir antiviral development. In November 2025, Vaxart, Inc. entered an exclusive worldwide license and collaboration agreement with Dynavax Technologies Corporation for its COVID-19 oral vaccine program, receiving a $25 million upfront fee and $5 million equity investment while retaining responsibility through Phase 2b completion and FDA End-of-Phase 2 meeting, with potential milestones up to $195 million regulatory and $425 million sales; the company reported positive Phase 1 data for second-generation norovirus constructs showing enhanced antibody responses, Q3 2025 revenue of $72.4 million driven by government contracts versus $4.9 million prior year, and cash position of $28.8 million extending runway into Q2 2027.
Company News
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 Earnings Call Highlights
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart to Participate in BTIG Biotechnology Conference 2026
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Vaxart Announces Results of Annual Meeting of Stockholders
Vaxart Announces Results of Annual Meeting of Stockholders
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
Vaxart to Participate in BTIG Infectious Disease Day 2026
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY